Eye-Care Focused Nutritional Biotechnology Company Reformulates Flagship Multiple: Macula Complete
January 06, 2010
COLORADO SPRINGS, Colo., Jan 06, 2010 /PRNewswire via COMTEX/ ---- Biosyntrx, a privately held eye-care-focused biotechnology company, leads the eye-specific supplement industry with cost-effective evidence-based formulas, with particular attention paid to formulation design and raw ingredient selection.
Macula Complete, the most inclusive and best-selling full-spectrum vitamin/mineral/antioxidant multiple designed for optimal eye and body health was reformulated to increase Vitamin D from 1,200 IU to 2,000 IU of Vitamin D3 to address the Vitamin D deficiency epidemic, a biochemical-balance of all eight parts of Vitamin E tocopherols and tocotrienols, including DeltaGold tocotrienols, 100 mg of Trans-Resveratrol, 100 mg Green Tea, as well as the 200 mg of Acetyl-L-Carnitine, 30 mg of CoQ10, and 150 mg of Lipoic Acid for optimal mitochondrial, antiangeogenic, anti-inflammatory activity and cellular delivery.
"Our team of thought-leading ophthalmologists, optometrists, biochemists and molecular biologists are committed to developing innovative eye and body health nutritional formulations that reflect the most current nutrition science, improved patient compliance, and meets the most stringent science-based regulatory and manufacturing standards," said Biosyntrx CEO/Chief Research Officer, Ellen Troyer, MT, MA, of Colorado Springs, CO.
"Biosyntrx has established a reputation for being first-to-market with full-spectrum multiple formulations that thousands of case studies and repeat buyers suggest protect eye health," said Spencer Thornton, MD, Biosyntrx President/Chief Medical Officer of Nashville, TN.
About Biosyntrx, Inc.
Biosyntrx is focused on developing state-of-the-art nutritional formulations that support optimal eye and body health. It's an industry-leading seven-year-old company incorporated in Lexington, South Carolina with research, development and marketing offices in Colorado Springs, CO.
The Biosyntrx Scientific Advisory